ASH 2024 | A predictive model for advanced vs indolent systemic mastocytosis based on peripheral blood testing

The diagnosis of systemic mastocytosis is difficult. Pathologists will come with a diagnosis of systemic mastocytosis, but it’s up to the clinician to differentiate between an indolent versus an advanced course of the disease using some really arcaic B and C findings, and it’s very complicated, even for a seasoned veteran like myself. And so what we did is we came up with some mathematical modeling using basic laboratory findings to discriminate between indolent versus advanced disease. We used patients that were enrolled on the Pioneer avapritinib study, which was only indolent systemic mastocytosis, and patients who enrolled on the Explorer and Pathfinder studies, and both of those included only advanced systemic mastocytosis. So with 93% predictive capabilities, we were able to differentiate using just simple parameters between indolent and advanced systemic mastocytosis. We then took a large cohort of patients, almost 200 patients from the Dana-Farber as a validation set. And we were also able to corroborate this modeling to differentiate these two entities. And we think that in the future, this is going to assist clinicians who may not be as versed in the differential subtypes of systemic mastocytosis in determining which stage or which disease a patient has, which is important for both prognosis as well as therapeutic treatment.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.